Today, CombiGene Celebrates the World Lipodystrophy Day

Mar 31, 2020

Currently, there is no cure for lipodystrophy, and just the secondary complications can be treated. Lipodystrophy is a rare and very serious disease. CombiGene continues to develop the pre-clinical work in the CGT2 project for the treatment of lipodystrophy at rapid pace. Patient organizations around Europe are celebrating the day, see link below.
http://www.aelip.co.uk/world-day-of-lipodystrophies.asp

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook